Abstract
Photodynamic therapy (PDT) involves the light activation of a drug within a tumor causing selective tumor cell death. Unfortunately, some photosensitizing drugs have been associated with adverse reactions in veterinary patients. Zinc phthalocyanine tetrasulfonate (ZnPcS 4) is a promising second-generation photosensitizer for use in veterinary medicine, however, it cannot be applied clinically until safety and efficacy data are available. ZnPcS 4 was given to Swiss Webster mice to assess acute toxicity. Doses >100 mg/kg were associated with acute toxicity and mortality, and doses >100 mg/kg resulted in renal tubular nephrosis, suggesting that the minimum toxic dose is approximately 100 mg/kg. Based on these data, a Phase I clinical trial of ZnPcS 4-based PDT in tumor-bearing dogs is underway, with ZnPcS 4 doses up to 2 mg/kg producing no apparent toxicity. Tumor response has been observed after ZnPcS 4-based PDT using doses as low as 0.25 mg/kg, suggesting that conventional phase I clinical trials may not be appropriate for PDT protocols.
Original language | English (US) |
---|---|
Article number | 124 |
Pages (from-to) | 624-630 |
Number of pages | 7 |
Journal | Progress in Biomedical Optics and Imaging - Proceedings of SPIE |
Volume | 5686 |
DOIs | |
State | Published - 2005 |
Externally published | Yes |
Event | Photonic Therapeutics and Diagnostics - San Jose, CA, United States Duration: Jan 22 2005 → Jan 25 2005 |
Keywords
- Animal model
- Canine
- Clinical trial
- Dog
- Photodynamic therapy
- Second-generation photosensitizer